Pfizer's Epogen Biosimilar Retacrit Launches At 33% Off In A US Market Where Amgen's Already Competitive

Retacrit – a biosimilar of Amgen's Epogen and J&J's Procrit – will launch at aggressive discounts to the original anemia products in a market where Amgen's already proven there's a tough fight for market share.

Sterile bottles and ampoules on the dispensing line.Sealed ampoules with medicine.Sterile capsules for injection. Bottles on the bottling line of the pharmaceutical plant.

Pfizer Inc. said on Nov. 14 that it launched the anemia drug Retacrit – the first US biosimilar for Amgen Inc.'s Epogen and Johnson & Johnson's Procrit – at 33.5% and 57.1% discounts, respectively, to the reference products as it gears up to win share in a market where competition already is fierce.

Epogen (epoetin alfa) sales have been in decline for the past few years due to biosimilars outside the US and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from New Products

Novartis Upbeat Even With Entresto Expiry Looming

 
• By 

Swiss major confident that new oncology drugs will fill revenue gap.

J&J Delivers In Q2 Despite Stelara Drop, Raising Guidance

 

Stelara revenues declined 42.7% in the quarter due to biosimilars, but innovative medicines grew 4.9%, surpassing $15bn for the quarter. Although pharma tariffs could be coming, the firm said the impact continues to be hard to predict.

Sun’s Alopecia Treatment Debuts In US - Can It Make Up For Lost Time?

 

Sun’s Leqselvi goes up against Lilly's Olumiant and Pfizer's Litfulo, which currently has the broadest label, in the US alopecia market. Can it shake things up early, amid growing activity in the space with several new mechanisms of action being investigated?

In Brief: Nanoscope Ploughs Forward With FDA Application For Retinitis Pigmentosa Gene Therapy

 
• By 

Nanoscope’s experimental gene therapy, MCO-010, is designed to target the broader retinitis pigmentosa population, regardless of the underlying gene mutation, with a completed US regulatory submission expected in early 2026.

More from Scrip

In partnership with

Podcast: Strategic Insights into the RNA Market

Discover the latest trends in RNA-based therapeutics and learn how sponsors can successfully navigate the road to next generation innovation. Listen in as Citeline chats with the Director of Therapeutics at Novotech, a CRO experienced in RNA development.

China Sentences Astellas Employee To 3.5 Years In Prison On Spy Charges

 
• By 

An employee of Astellas faces three and a half years in prison after sentencing by a court in China on espionage charges.

Sarepta Restructures, Cuts 500 Jobs As Elevidys-Related Deaths Impact Sales

 
• By 

After a second quarter of declining Elevidys sales following two deaths of DMD patients treated with the gene therapy, Sarepta is cutting costs to fund remaining programs and meet debt requirements.